. 2016 Oct 20;12(10):e1005950. doi: 10.1371/journal.ppat.1005950

Table 1. Summary of names, PubChem IDs, and the minimal concentrations defined to enhance HSV-2 infection^*.

The epigenetics compound library contains 129 small molecule compounds that are classified into inhibitors of histone deacetylases (HDACi), lysine demethylases, histone acetyltransferases (HATs), DNA methyltransferases (Dnmts), and the epigenetic reader domain inhibitors, to name a few. Thirteen compounds showed enhancement effect on infection, while no compounds showed inhibitory effect. To quantitatively describe their effect on HSV-2 infection, we determined the concentration that would cause 20% changes in cell viability from HSV-2-infected controls. In this regard, the compounds were series diluted and tested on Vero cells in triplicated samples. An MOI of 1 was used for infections. HSV infection causes cytolytic effect that was determined at 48–60 hr PI by an MTT assay.

Name	PubChem CID	EC₂₀ (nM)	Inhibitor of
Trichostatin A	444732	30	HDAC
Quisinostat	11538455	30	HDAC
CUDC-907	54575456	30	HDAC, PI3K
CUDC-101	24756910	100	HDAC
Givinostat	9804992	100	HDAC
HDAC-42	6918848	100	HDAC
Pracinostat	49855250	300	HDAC
Scriptaid	5186	300	HDAC
Tubastatin A	57336514	3000	HDAC
JQ1	46907787	50	BET bromodomain
PFI-1	71271629	100	BET bromodomain
I-BET-762	46943432	300	BET bromodomain
TG101348	16722836	1000	BET bromodomain, JAK

* The concentration that causes a 20% (EC₂₀) reduction in OD readings was given as a minimal concentration required to enhance HSV infection.

Table 1. Summary of names, PubChem IDs, and the minimal concentrations defined to enhance HSV-2 infection*.

Table 1. Summary of names, PubChem IDs, and the minimal concentrations defined to enhance HSV-2 infection^*.